Long-term health study for people with lymphoma treated with liso-cel
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at patients with a type of lymphoma (follicular lymphoma) who have already received a CAR T-cell therapy called liso-cel. Researchers want to track their health over time and see how well the treatment works and how safe it is in routine medical care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with follicular lymphoma (grades 1, 2, or 3a) that came back or did not respond to other treatments.
- You have already received at least one infusion of liso-cel (also called Breyanzi) as part of your regular medical care in the United States.
- You are not taking part in any other research study at the time you received liso-cel.
- You did not receive liso-cel for a different type of lymphoma called grade 3b follicular lymphoma.
- You received a standard, approved liso-cel product, not a custom or experimental one.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who have already been treated with Relma-cel, a type of CAR-T cell therapy for blood cancers. It is not a new treatment but a way to collect more information about how Relma-cel works over time.
This trial tests a new car t-cell treatment (axicabtagene ciloleucel) for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if this therapy can help control the lymphoma.
This study looks at patients with mantle cell lymphoma who have already received a treatment called lisocabtagene maraleucel (Liso-cel) as part of standard care. It helps researchers understand how well the therapy works in real-world use.
This study looks at people with CLL or SLL who have already been treated with the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) in routine medical care. It collects information about how well the treatment works and how patients are doing over time, without giving any new treatment.
This trial provides access to a CAR T-cell therapy called liso-cel for people whose own treatment batch didn't meet quality standards but who might still benefit. It's a way to receive the therapy when re-making it isn't possible.
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.